Pricing Log in Create free account

Phathom Pharmaceuticals, Inc. (PHAT) vs Solid Biosciences Inc. (SLDB)

Phathom Pharmaceuticals, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Phathom Pharmaceuticals, Inc. and Solid Biosciences Inc. are of similar size ($615.5M and $606.8M). Solid Biosciences Inc. has the higher net margin (0.00% vs −41.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Phathom Pharmaceuticals, Inc. leads on 10 and Solid Biosciences Inc. on 4.

Valuation

Metric PHAT SLDB Biotechnology median
P/E n/m n/m 8.50
P/S 2.42 70.64 9.71
P/B n/m 2.12 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 2.39 37.04 9.21
Earnings yield (18.50%) (34.54%) (33.15%)
Free cash flow yield (6.37%) (23.62%) (25.50%)

Profitability

Metric PHAT SLDB Biotechnology median
Gross margin 82.92% 0.00% 65.16%
Operating margin (16.96%) 0.00% 0.00%
Net margin (41.34%) 0.00% 0.00%
Free cash flow margin (15.40%) 0.00% 0.00%
Return on equity 26.42% (65.50%) (56.36%)
Return on assets (34.32%) (56.83%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PHAT SLDB Biotechnology median
Revenue growth (TTM) 110.16% — 6.02%
EPS growth (last fiscal year) 42.72% 34.97% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PHAT SLDB Biotechnology median
Debt to equity (0.48) 0.00 0.00
Current ratio 1.92 13.82 4.72
Net debt to EBITDA (0.51) 1.05 0.96

Dividend

Metric PHAT SLDB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PHAT SLDB Biotechnology median
Market cap 606.76m 615.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack